Progress of Neoadjuvant Immunotherapy for Non-small Cell Lung Cancer.
10.3779/j.issn.1009-3419.2022.101.29
- Author:
Chao GUO
1
;
Jiaqi ZHANG
1
;
Shanqing LI
1
Author Information
1. Department of Thoracic Surgery, Peking Union Medical College Hospital,
Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.
- Publication Type:Journal Article
- Keywords:
Immunotherapy;
Lung neoplasms;
Neoadjuvant therapy
- MeSH:
Antineoplastic Agents, Immunological/therapeutic use*;
Carcinoma, Non-Small-Cell Lung/pathology*;
Humans;
Immunotherapy/methods*;
Lung Neoplasms/pathology*;
Neoadjuvant Therapy;
Nivolumab/therapeutic use*
- From:
Chinese Journal of Lung Cancer
2022;25(7):524-533
- CountryChina
- Language:Chinese
-
Abstract:
Neoadjuvant immunotherapy, including neoadjuvant single- or dual-drug immunotherapy or combined immunotherapy with chemotherapy or radiotherapy, has witnessed a rapid development in non-small cell lung cancer. Clinical trials exhibited the encouraging pathological responses and certain clinical benefits in selected patients, with tolerable toxicity. Nivolumab with chemotherapy has been approved by Food and Drug Administration (FDA) as the first immunotherapy-based treatment for non-small cell lung cancer in the neoadjuvant treatment setting. There is the need for further evaluation of long-term efficacy, side effects or surgical issues for neoadjuvant immunotherapy in non-small cell lung cancer.
.
